Navigation Links
NOVAVAX Elects Richard H. Douglas to its Board of Directors
Date:8/6/2010

ROCKVILLE, Md., Aug. 6 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today the appointment of Richard Douglas, Ph.D. to its board of directors.  Dr. Douglas is currently Senior Vice President, Corporate Development at Genzyme Corp.  As a leader of Genzyme's Corporate Development team, Dr. Douglas has been involved in numerous acquisitions, licenses, joint ventures and strategic alliances as well as Genzyme's venture investments.  He has served in a variety of corporate and product development positions with Genzyme since he joined Integrated Genetics (now Genzyme) as a staff scientist in 1982.

Novavax Chairman Stanley Erck stated:  "Richard has more than twenty-five years of corporate, business and product development experience at Genzyme which will be extremely valuable to Novavax as we advance our vaccine candidates.  His expertise in business development, technology assessment and protein chemistry will be especially helpful in guiding our future discovery, development and commercialization programs.  We welcome his counsel and contributions to our future success."

Dr. Douglas currently serves on the national advisory board of the University of Michigan Technology Transfer Office and previously served as a director of Iomai Corporation and Synthon Chiragenics.  He received his doctorate in biochemistry from the University of California at Berkeley and his bachelor's degree in chemistry from the University of Michigan.

About Novavax

Novavax, Inc. is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology.  The company produces potent VLP-based recombinant vaccines utilizing new and efficient manufacturing approaches.  Novavax is committed to using its VLP technology to create country-specific vaccine solutions.  The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India.  Additional information about Novavax is available on the company's website: www.novavax.com.

Cautionary Note Regarding Forward-Looking Statements

Statements herein relating to future performance, conditions or strategies and other matters, including expectations regarding the development of the Company's vaccines, are forward-looking statements.  Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time.  We caution readers not to place significant reliance on the forward-looking statements contained in this release.  Factors that may cause actual results to differ materially from the results discussed in forward-looking statements or historical experience include, among other things, the following including the Company's ability to progress its product candidates in preclinical or clinical trials; clinical trial results; even if the data from preclinical studies or clinical trials is positive, the product may not prove to be safe and efficacious; the rate and progress of manufacturing scale-up; and the Company's ability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity or debt financing or otherwise, and other factors referenced herein.  Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov, including the factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2009, as updated by our Quarterly Report on Form 10-Q for the quarters ended March 31, 2010.  These forward-looking statements speak only as of the date of this earnings release and Novavax assumes no duty to update such statements.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Novavax Announces Appointment of Dr. Gregory Glenn as Chief Scientific Officer
2. Novavax Announces Manufacturing Management Appointments
3. Novavax Announces Publication of a Pre-clinical Study with its Pandemic 2009 H1N1 Influenza Virus-Like Particle (VLP) Vaccine
4. NOVAVAX Completes Enrollment of Pivotal H1N1 Influenza Vaccine Clinical Trial in Mexico
5. NOVAVAX to Present at the 12th Annual BIO CEO & Investor Conference
6. NOVAVAX to Present at Phacilitate Vaccine Forum Washington 2010
7. NOVAVAX Announces Positive Preclinical Results for its Respiratory Syncytial Virus (RSV) Vaccine Candidate
8. NOVAVAX to Present at the Piper Jaffray 21st Annual Health Care Conference
9. NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults
10. Novavax Prices Public Offering of Common Stock
11. NOVAVAX Completes First Stage of Enrollment in Pivotal H1N1 Influenza Vaccine Study in the Country of Mexico
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... the launch of the Supplyframe Design Lab . Located in Pasadena, Calif., ... the future of how hardware projects are designed, built and brought to market. ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... the trading session at 4,833.32, down 0.22%; the Dow Jones ... the S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ... BIND Therapeutics Inc. (NASDAQ: BIND ). Learn more ...
Breaking Biology Technology:
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
Breaking Biology News(10 mins):